Neurogenic orthostatic hypotension (NOH) Market Analysis By Types (Parkinsonas disease, Diabetes, Dopamine beta hydroxylase (DBH) deficiency, MSA, PAF, Others), By Applications (Clinic, Hospital) & Forecast

  • 4/28/2023
  • 290
  • Healthcare & Life Sciences
Neurogenic orthostatic hypotension (NOH) is a rare neurological disorder that affects the autonomic nervous system, leading to a significant drop in blood pressure upon standing. This can cause symptoms such as dizziness, fainting, and falls.

The global market for NOH treatment is expected to grow significantly in the coming years, primarily due to the increasing prevalence of the condition and the availability of advanced treatment options. The most common treatment options for NOH include lifestyle modifications, pharmacotherapy, and non-pharmacologic interventions such as physical therapy and compression stockings. Medications such as midodrine, fludrocortisone, and droxidopa are commonly used to manage symptoms.
The key players operating in the NOH treatment market include Lundbeck A/S, Chelsea Therapeutics, Inc., Amgen Inc., H. Lundbeck A/S, and Pfizer, Inc. These companies are focusing on developing new and innovative treatment options to improve patient outcomes and reduce the side effects associated with current treatment options.

Overall, the NOH treatment market is expected to experience steady growth in the coming years due to the increasing prevalence of the condition and the availability of effective treatment options. However, the high cost of treatment and the limited availability of advanced treatment options in some regions may hinder market growth to some extent. Additionally, the limited awareness of the condition among patients and healthcare professionals may also be a challenge for market growth.

Report Scope

Report Attributes


Market Size in 2022

USD 376 Million

Market Forecast in 2032

USD 824 Million

CAGR % 2023-2031


Base Year


Historic Data


Forecast Period


Report USP

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Type, By Application

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

Key Companies

Sumitomo Pharmaceuticals, Chelsea Therapeutics (Droxidopa), Shire PLC (ProAmatine®), NORTHERA® (Droxidopa)

Segment Overview
Neurogenic orthostatic hypotension (nOH) is a type of low blood pressure that occurs when a person stands up from a sitting or lying down position. It is caused by an autonomic nervous system dysfunction, which leads to a decrease in blood pressure and an inadequate blood flow to the brain.
The market segment for nOH includes patients who suffer from this condition and require medical intervention to manage their symptoms. This includes medications, lifestyle changes, and other treatments.
The market for nOH treatments is still relatively small, but it is expected to grow as more people are diagnosed with this condition. Some of the current medications used to treat nOH include fludrocortisone, midodrine, and droxidopa.

In addition to medication, patients with nOH may also benefit from lifestyle changes such as increasing salt intake, staying hydrated, and avoiding sudden changes in position. There is also ongoing research into new treatments for nOH, including gene therapy and stem cell therapy.
Overall, the nOH market segment is expected to grow as awareness of this condition increases and more effective treatments become available.

Geographical Overview
Neurogenic orthostatic hypotension (NOH) is a rare disorder that affects the autonomic nervous system and is characterized by a sudden drop in blood pressure upon standing. The market for NOH is relatively small, with a limited number of approved treatments available.
In terms of geography, the NOH market is primarily focused in developed regions such as North America, Europe, and Japan, where the prevalence of the disease is higher due to the aging population. The United States is the largest market for NOH, followed by Europe and Japan.
In recent years, there has been an increased focus on developing treatments for NOH, which has led to the introduction of new therapies in the market. Some of the major players in the NOH market include Lundbeck, Northera, and Droxidopa.
Overall, the NOH market is expected to grow in the coming years as more patients are diagnosed and as new treatments are developed and approved. However, due to the rarity of the disease and the limited patient population, the market is likely to remain relatively small compared to other therapeutic areas.

COVID Impact
Neurogenic Orthostatic Hypotension (NOH) is a type of low blood pressure that occurs when a person stands up from a sitting or lying position. It is caused by dysfunction of the autonomic nervous system and can be a symptom of various underlying conditions such as Parkinson's disease, multiple system atrophy, or pure autonomic failure.
The COVID-19 pandemic has had a significant impact on the healthcare industry and has affected the diagnosis, treatment, and management of various medical conditions, including NOH.

Here are some of the ways COVID-19 has impacted the NOH market:
1. Delayed Diagnosis: With the pandemic causing significant disruptions to healthcare services, many people may have delayed seeking medical attention for their symptoms. As a result, some people with NOH may have gone undiagnosed, leading to a smaller patient pool and reduced demand for NOH treatments.
2. Changes in Treatment Patterns: The pandemic has also led to changes in the way medical care is delivered. Telemedicine and remote consultations have become more prevalent, and in-person visits to healthcare facilities have decreased. These changes may have affected the way NOH patients are treated and managed.
3. Disruptions to Clinical Trials: Many clinical trials investigating potential NOH treatments may have been delayed or disrupted due to the pandemic. This could potentially delay the development and approval of new NOH therapies.
Despite these challenges, the NOH market is still expected to grow in the coming years, driven by an increasing prevalence of underlying conditions such as Parkinson's disease and multiple system atrophy. Additionally, the development of new NOH treatments may also provide opportunities for growth in the market.

Competitive Analysis
Neurogenic orthostatic hypotension (NOH) is a type of orthostatic hypotension that is caused by dysfunction of the autonomic nervous system. It is a relatively rare condition, affecting approximately 200,000 to 300,000 people in the United States.
Currently, there are only a few drugs approved by the FDA to treat NOH, including midodrine, droxidopa, and pyridostigmine. The market for NOH treatment is relatively small, but growing as awareness of the condition increases and new treatments are developed.

The key players in the NOH market include pharmaceutical companies such as Lundbeck, Chelsea Therapeutics, and Northera Pharmaceuticals. Lundbeck is a major player in the NOH market, with its drug, Northera (droxidopa), being one of the only FDA-approved treatments for the condition. Chelsea Therapeutics is another company that has developed a drug for NOH, called Northera, which is currently in clinical trials.
In addition to these established players, there are several other companies that are developing new treatments for NOH. For example, Theravance Biopharma is developing a drug called TD-9855, which is currently in Phase 3 clinical trials. This drug works by activating the norepinephrine transporter, which increases the release of norepinephrine in the brain and can help regulate blood pressure.

Overall, the NOH market is relatively small, but there is significant potential for growth as awareness of the condition increases and new treatments are developed. As more companies enter the market and competition increases, it is likely that we will see further innovation and development of new treatments for this condition.

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).


The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.


Select a license type that suits your business needs

Single User Access

US $4250

Only Four Thousand Two Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5250

Only Five Thousand Two Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $6250

Only Six Thousand Two Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI